Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously
treated locally advanced unresectable or metastatic solid tumors with mismatched repair
deficient (dMMR) or microsatellite instability-high (MSI-H) will be treated with anti-PD-1
Monoclonal Antibody Tislelizumab (BGB-A317). Efficacy and safety will be assessed. A short
description of the clinical study, including a brief statement of the clinical study's
hypothesis, written in language intended for the lay public.